Logo image of IDXX

IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IDXX - US45168D1046 - Common Stock

701.865 USD
-5.63 (-0.8%)
Last: 12/12/2025, 11:33:52 AM
Fundamental Rating

7

Overall IDXX gets a fundamental rating of 7 out of 10. We evaluated IDXX against 187 industry peers in the Health Care Equipment & Supplies industry. IDXX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IDXX is not valued too expensively and it also shows a decent growth rate. With these ratings, IDXX could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

IDXX had positive earnings in the past year.
In the past year IDXX had a positive cash flow from operations.
In the past 5 years IDXX has always been profitable.
In the past 5 years IDXX always reported a positive cash flow from operatings.
IDXX Yearly Net Income VS EBIT VS OCF VS FCFIDXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

Looking at the Return On Assets, with a value of 30.34%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Equity of IDXX (65.81%) is better than 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 40.25%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
IDXX had an Average Return On Invested Capital over the past 3 years of 35.08%. This is significantly above the industry average of 8.81%.
The 3 year average ROIC (35.08%) for IDXX is below the current ROIC(40.25%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 30.34%
ROE 65.81%
ROIC 40.25%
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
IDXX Yearly ROA, ROE, ROICIDXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin of IDXX (24.65%) is better than 95.19% of its industry peers.
IDXX's Profit Margin has improved in the last couple of years.
IDXX has a better Operating Margin (31.34%) than 98.93% of its industry peers.
IDXX's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 61.72%, IDXX is doing good in the industry, outperforming 62.57% of the companies in the same industry.
In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
Industry RankSector Rank
OM 31.34%
PM (TTM) 24.65%
GM 61.72%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
IDXX Yearly Profit, Operating, Gross MarginsIDXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IDXX is creating value.
The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
Compared to 5 years ago, IDXX has less shares outstanding
IDXX has a better debt/assets ratio than last year.
IDXX Yearly Shares OutstandingIDXX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDXX Yearly Total Debt VS Total AssetsIDXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 23.69 indicates that IDXX is not in any danger for bankruptcy at the moment.
IDXX has a better Altman-Z score (23.69) than 96.26% of its industry peers.
The Debt to FCF ratio of IDXX is 1.04, which is an excellent value as it means it would take IDXX, only 1.04 years of fcf income to pay off all of its debts.
IDXX has a better Debt to FCF ratio (1.04) than 90.91% of its industry peers.
IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
IDXX has a Debt to Equity ratio (0.53) which is comparable to the rest of the industry.
Although IDXX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 1.04
Altman-Z 23.69
ROIC/WACC4.42
WACC9.1%
IDXX Yearly LT Debt VS Equity VS FCFIDXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

IDXX has a Current Ratio of 1.18. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IDXX (1.18) is worse than 83.42% of its industry peers.
A Quick Ratio of 0.87 indicates that IDXX may have some problems paying its short term obligations.
IDXX has a worse Quick ratio (0.87) than 81.82% of its industry peers.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 0.87
IDXX Yearly Current Assets VS Current LiabilitesIDXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

6

3. Growth

3.1 Past

IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.16%, which is quite good.
IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.18% yearly.
The Revenue has grown by 8.39% in the past year. This is quite good.
Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%

3.2 Future

IDXX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.81% yearly.
IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.18% yearly.
EPS Next Y16.93%
EPS Next 2Y14.43%
EPS Next 3Y14.3%
EPS Next 5Y13.81%
Revenue Next Year10.46%
Revenue Next 2Y9.62%
Revenue Next 3Y9.46%
Revenue Next 5Y9.18%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
IDXX Yearly Revenue VS EstimatesIDXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
IDXX Yearly EPS VS EstimatesIDXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 55.66, which means the current valuation is very expensive for IDXX.
IDXX's Price/Earnings ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 68.45% of the companies in the same industry.
When comparing the Price/Earnings ratio of IDXX to the average of the S&P500 Index (26.76), we can say IDXX is valued expensively.
The Price/Forward Earnings ratio is 47.64, which means the current valuation is very expensive for IDXX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 69.52% of the companies listed in the same industry.
IDXX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.96.
Industry RankSector Rank
PE 55.66
Fwd PE 47.64
IDXX Price Earnings VS Forward Price EarningsIDXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IDXX is valued a bit cheaper than the industry average as 68.45% of the companies are valued more expensively.
72.73% of the companies in the same industry are more expensive than IDXX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 59.61
EV/EBITDA 39.28
IDXX Per share dataIDXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of IDXX may justify a higher PE ratio.
A more expensive valuation may be justified as IDXX's earnings are expected to grow with 14.30% in the coming years.
PEG (NY)3.29
PEG (5Y)3.06
EPS Next 2Y14.43%
EPS Next 3Y14.3%

0

5. Dividend

5.1 Amount

IDXX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IDEXX LABORATORIES INC

NASDAQ:IDXX (12/12/2025, 11:33:52 AM)

701.865

-5.63 (-0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-02 2026-02-02/amc
Inst Owners94.91%
Inst Owner Change-0.94%
Ins Owners0.21%
Ins Owner Change2.18%
Market Cap56.04B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80.95
Price Target773.18 (10.16%)
Short Float %2.14%
Short Ratio3.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)10.84%
PT rev (3m)11.82%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)1.8%
EPS NY rev (1m)2.24%
EPS NY rev (3m)2.34%
Revenue NQ rev (1m)0.37%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)1.25%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE 55.66
Fwd PE 47.64
P/S 13.45
P/FCF 59.61
P/OCF 51.51
P/B 35.9
P/tB 54.27
EV/EBITDA 39.28
EPS(TTM)12.61
EY1.8%
EPS(NY)14.73
Fwd EY2.1%
FCF(TTM)11.77
FCFY1.68%
OCF(TTM)13.63
OCFY1.94%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.29
PEG (5Y)3.06
Graham Number74.48
Profitability
Industry RankSector Rank
ROA 30.34%
ROE 65.81%
ROCE 61.18%
ROIC 40.25%
ROICexc 43.77%
ROICexgc 56.25%
OM 31.34%
PM (TTM) 24.65%
GM 61.72%
FCFM 22.56%
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 1.04
Debt/EBITDA 0.57
Cap/Depr 105.48%
Cap/Sales 3.55%
Interest Coverage 250
Cash Conversion 75.23%
Profit Quality 91.51%
Current Ratio 1.18
Quick Ratio 0.87
Altman-Z 23.69
F-Score8
WACC9.1%
ROIC/WACC4.42
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y16.93%
EPS Next 2Y14.43%
EPS Next 3Y14.3%
EPS Next 5Y13.81%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year10.46%
Revenue Next 2Y9.62%
Revenue Next 3Y9.46%
Revenue Next 5Y9.18%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year33.13%
EBIT Next 3Y18.09%
EBIT Next 5Y14.77%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%

IDEXX LABORATORIES INC / IDXX FAQ

What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to IDXX.


Can you provide the valuation status for IDEXX LABORATORIES INC?

ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.


Can you provide the profitability details for IDEXX LABORATORIES INC?

IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.


What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 55.66 and the Price/Book (PB) ratio is 35.9.


Can you provide the expected EPS growth for IDXX stock?

The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 16.93% in the next year.